Can a modified vitamin a pill save sight in dry AMD?
NCT ID NCT03845582
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a daily pill called ALK-001, a modified form of vitamin A, to see if it can slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 300 people with the condition took either the drug or a placebo for 24 months. Researchers measured changes in the size of the atrophy and checked for side effects and vision changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALK-001 (a modified form of vitamin A)
What this could lead to
If successful, this could slow the progression of geographic atrophy, helping preserve vision in people with dry age-related macular degeneration.
What could go wrong
This is a mid-stage trial with only 200 participants, so results may not apply to everyone. The treatment may not slow vision loss or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alkeus Site
Phoenix, Arizona, 85053, United States
-
Alkeus Site
Beverly Hills, California, 90211, United States
-
Alkeus Site
Lakewood, Colorado, 80228, United States
-
Alkeus Site
Clearwater, Florida, 33761, United States
-
Alkeus Site
Fort Myers, Florida, 33912, United States
-
Alkeus Site
Gainesville, Florida, 32601, United States
-
Alkeus Site
Tampa, Florida, 33609, United States
-
Alkeus Site
Winter Haven, Florida, 33880, United States
-
Alkeus Site
Bloomington, Illinois, 61704, United States
-
Alkeus Site
Lexington, Kentucky, 40509, United States
-
Alkeus Site
Chevy Chase, Maryland, 20815, United States
-
Alkeus Site
Worcester, Massachusetts, 01605, United States
-
Alkeus Site
Grand Rapids, Michigan, 49546, United States
-
Alkeus Site
Edina, Minnesota, 55435, United States
-
Alkeus Site
Northfield, New Jersey, 08225, United States
-
Alkeus Site
Great Neck, New York, 11021, United States
-
Alkeus Site
Hauppauge, New York, 11788, United States
-
Alkeus Site
Cleveland, Ohio, 44122, United States
-
Alkeus Site
Ashland, Oregon, 97520, United States
-
Alkeus Site
Houston, Texas, 77025, United States
-
Alkeus Site
Fairfax, Virginia, 22031, United States
-
Alkeus Site
Silverdale, Washington, 98383, United States
-
Alkeus Site-1
San Antonio, Texas, 78240, United States
-
Alkeus Site-2
San Antonio, Texas, 78240, United States